Skip to main content
OpenTrials
Completed

NCT Number: NCT03740568

Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes.

Transferring an euploid embryo avoids one of the main reasons of miscarriage and implantation failure (1), overcoming confounding factors such as embryo ploidy or maternal age. Frozen Euploid Embryo Transfer (FEET) is routinely performed under standard hormone replacement therapy (HRT) and could be considered the best model for evaluating the impact of the endometrial preparation in clinical pregnancy rate and also in miscarriage rate.

Recently several authors have paid attention to serum progesterone (P) as a possible factor influencing Frozen Embryo Transfer (FET) outcomes. P plays an important role in endometrial gland formation, embryonic implantation and pregnancy maintenance. Labarta et al. (2) described in blastocyst FET performed under HRT that serum P <9.2 ng/mL measured on the transfer day is associated to significantly lower ongoing pregnancy rate (OR 0.297, 95% CI:0.113-0.779).

Recently the investigators have analyzed 244 FEET performed under HRT in a retrospective study (3). Preimplantation genetic testing for aneuploidies (PGT-A) was carried out as previously described (4). Embryos that reached the blastocyst stage were biopsied and frozen immediately afterwards using the vitrification method (5). Euploid embryos were transferred in a subsequent cycle under HRT. Serum P was analyzed the day previous to FEET. Patients with serum P <10.6 ng/mL had significantly higher miscarriage rate (26.6% vs 9.5%, p=0.007) and lower live birth rate (47.5% vs 62.3 %, p= 0.029) than those with serum P >10.6 ng/mL. The investigators also observed that patients with serum P >13.1 ng/mL had the lowest miscarriage rate (9.1%) and the highest live birth rate (65.6%). The worst outcomes were observed when serum P was <8.06 ng /mL (41% live birth rate and 32.4% miscarriage rate).

As miscarriage was higher among FEET cycles with serum P <10.6 ng/ml, the investigators hypothesize that altering the progesterone supplementation scheme could potentially reduce miscarriage rates and increase live birth rate. The purpose of this study is to modify the standard progesterone supplementation in FEET under HRT (vaginal micronized progesterone 200 mg every 8 hours) (6) according to serum P measured not only on the day prior to transfer but also on Beta subunit of Human Chorionic Gonadotropin (β-hCG) analysis day, and to probe if this intervention reduces miscarriage rate and increases pregnancy outcome.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Departamento Ginecología, Obstetricia y Reproducción . Hospital Universitari Dexeus

Barcelona, 08028, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • FEET of at least one single embryo
  • HRT
  • Endometrial thickness >= 6 mm measured day 4 of progesterone supplementation

Exclusion criteria

  • Patients with mosaic embryos.
  • Uterine abnormality.
  • Natural cycle protocol

Treatment and study plan

Low Progesterone

Drug

Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4 (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night) New Progesterone analysis on D5 before warming the embryo. Group 2a (Canceled Group, P on D5 <10.64 ng/mL): cancel PGT-FET. Scheduling a new procedure under different P supplementation.

Group 2b (Restored Progesterone Group, P on D5 >10.64 ng/mL): continue HRT as previously described (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night). Warming and transfer the same day (D5)

Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:

If P is >10.64 ng /mL: the same P supplementation is continued. If P is <10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night

Normal Progesterone

Drug

Same Progesterone supplementation (vaginal micronized P 200mg/200mg/200mg) Warming and transfer on D5

Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:

If P is >10.64 ng /mL: the same P supplementation is continued. If P is <10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night

Primary outcomes

  1. Ongoing Pregnancy Rate (OPR)

    Time frame: 12 weeks after transfer procedure

    Ongoing Pregnancy Rate (OPR) beyond pregnancy week 12 in FEET according to serum P level and interventions on D4 and D5

  2. Miscarriage Rate (MR)

    Time frame: 12 weeks after transfer procedure

    Miscarriage Rate (MR) in FEET according to serum P level and interventions on D4 and D5.

  3. Concentration of serum P level

    Time frame: D4, D5 and D14 of P supplementation

    P level

Secondary outcomes

  1. Rate of cancellation due to lack of response in case of additional Psc dose on D4.

    Time frame: Day 5 of progesterone supplementation

  2. Rate of rescued cycles in case of additional Psc dose

    Time frame: Day 5 of progesterone supplementation

  3. Ongoing Pregnancy Rate and Live Birth Rate according to serum P level and interventions n D14

    Time frame: On day 14 of progesterone supplementation

  4. Live birth Rate (LBR)

    Time frame: 40 weeks after transfer procedure

    Live birth Rate (LBR) in FEET according to serum P level and interventions on D4 and D5 and D14.

Sponsors and collaborators

Lead sponsor

Fundacion Dexeus

Other

Collaborators

  • Dexeus Clinic Woman
  • Fundación Santiago Dexeus Font

Registry information

Official study title

Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Nov 14, 2018
Registry last updated
Jul 29, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.